On
#WorldCancerDay, ASBMB highlights research driving more precise cancer therapies.
In
#JBiolChem, Mayo Clinic researchers engineered a TIMP-1 protein variant that selectively inhibits MMP-9 & reduces invasion of triple-negative breast cancer cells.
www.asbmb.org/asbmb-today/...
Matrix metalloproteinase inhibitor reduces cancer invasion
Scientists at the Mayo Clinic engineered a TIMP-1 protein variant that selectively inhibits MMP-9 and reduces invasion of triple-negative breast cancer cells, offering a promising tool for targeted ca...
